
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
K 1.8K contracts
1
1

- Reported volume
- K 1.8K contracts
- Events
- 1
- Markets
- 1
Current odds
Snapshot from
As of Nov 22, 2026, 3:00 PM UTC, the highest-priced outcome on Kalshi is a full approval or an accelerated approval at 75.5%.
Kalshi
- a full approval or an accelerated approval75.5%
Yes prices. They are not order quotes; check each platform's rules, fees and live prices before trading.
AI Analysis
Trader mode: Market mechanics, assumptions and risks
K 1.8K contracts
Reported volume · provider units
1
Saved contracts
0
Same-question pairs
Source snapshot: Nov 22, 2026, 3:00 PM UTC
This analysis was written from an earlier market snapshot, so its prices may be older than the odds above.
Snapshot observed Nov 11, 2026, 12:00 AM UTC. This analysis describes that snapshot and is not a live news update.
What the contract measures
This market asks what the FDA's decision will be on saroglitazar, an oral small-molecule drug developed by Zydus Therapeutics, in 2026 [1]. The source says the drug is sold as Lipaglyn in India and is being evaluated in the EPICS-III trial as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications [1].
Under the stated rules, the market resolves to Yes if the FDA's decision is a full approval or an accelerated approval [1]. It resolves to No if the decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval, or if no decision is issued [1]. The rules also say the market will close early if the FDA issues a decision on saroglitazar before January 1, 2027 [1].
Reading the snapshot
The saved snapshot was observed at Nov 11, 2026, 12:00 AM UTC and retrieved at Nov 11, 2026, 12:52 AM UTC [1]. It contains one market on one platform, Kalshi, with a Yes price of 0.745 and a No price of 0.255 [1]. The coverage record marks this as a complete sample of the saved markets for this event, but the provider does not establish that it lists every possible real-world outcome [1].
These figures are snapshots, not executable quotes or verified probabilities. They show where the saved market stood at observation time. They do not explain why the price is where it is. The snapshot does not include volume or any count of traders, so it says nothing about the depth of the market.
The market data lists an end date of Jan 8, 2027, 3:00 PM UTC [1]. The source excerpt, however, states that the listed end time is not supplied [1]. Because these conflict, the close time should be verified at the provider before you rely on it. The title refers to 2026, while the listed end date falls in January 2027, and the early-close rule refers to a decision before January 1, 2027 [1]. The saved evidence does not explain how these dates interact beyond the quoted rules.
What remains uncertain
The evidence does not show whether the FDA has issued a decision, when one might occur, or any recent news about the application. The only source is a single excerpt for a single provider event. The price snapshot cannot tell you the outcome, and it may not reflect current prices.
References
- Kalshi: FDA decision: Saroglitazar by Zydus Therapeutics (in 2026). Provider data observed Nov 11, 2026, 12:00 AM UTC.
Snapshot observed Nov 11, 2026, 12:00 AM UTC. This analysis describes that snapshot and is not a live news update.
What the contract measures
The contract asks what the FDA's decision on Saroglitazar by Zydus Therapeutics will be in 2026 [1]. According to the saved rules, a full approval or an accelerated approval resolves to Yes. A denial (CRL issued), a withdrawal by the sponsor, a conditional approval, or no decision being issued resolves to No [1]. The excerpt also states that the market will close early if the FDA issues a decision on Saroglitazar before Jan 1, 2027 [1]. The drug is described as being evaluated for primary biliary cholangitis in the EPICS-III trial [1].
Reading the snapshot
The saved snapshot was observed at Nov 11, 2026, 12:00 AM UTC and retrieved at Nov 11, 2026, 12:52 AM UTC [1]. These prices describe that observation window, not a live quote. The Yes outcome was priced at 0.745 and the No outcome at 0.255 [1]. These are snapshot prices, not executable quotes or verified probabilities.
The contract is listed as active with an end date of Jan 8, 2027, 3:00 PM UTC [1]. However, the same provider excerpt says "Listed end time: not supplied." [1] These entries conflict, so readers should check the provider page before relying on any closing time. The end date should also not be read as an announced FDA decision date, because the supplied material does not give one.
The sample contains one market from one provider event. Coverage reports one included market out of one total, and partialSample is false [1]. The sample warning states that all saved markets are included but does not establish that the provider lists every possible real-world outcome [1]. With only this contract present, no comparison with other platforms or other outcomes is possible from this evidence.
What remains uncertain
The evidence does not explain why the prices sit where they do. It also does not provide trading volume, liquidity, or the number of participants holding either view. The supplied material contains no FDA decision, sponsor announcement, or recent news about Saroglitazar. The saved rules refer to a 2026 decision, but no further timing details are supplied. Readers should check the current contract page and any official regulatory communications directly.
References
- Kalshi: FDA decision: Saroglitazar by Zydus Therapeutics (in 2026). Provider data observed Nov 11, 2026, 12:00 AM UTC.
AI-generated analysis based on market data. Not financial advice.
Saved Nov 11, 2026 UTCThis article was written from an earlier market snapshot and may be out of date. Use the dated market data and provider rules above for current information.
Overview
This PredictPedia entry covers a Kalshi event asking how the U.S. Food and Drug Administration (FDA) will decide on saroglitazar, a drug developed by Zydus Therapeutics, during 2026 [1]. The event is titled "FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)" and is categorized under financials [1]. The contract is a yes or no question about the type of FDA decision. Under the listed rules, it resolves to Yes if the FDA's decision is a full approval or an accelerated approval [1]. It resolves to No if the decision is a denial (a complete response letter, or CRL), a withdrawal by the sponsor, or a conditional approval, or if no decision is issued [1]. The rules also state that the market will close early if the FDA issues a decision on saroglitazar before January 1, 2027 [1]. The saved market record lists an end date of January 8, 2027 at 15:00 UTC [1]. That date appears in the contract data and is not an announced FDA date. Saroglitazar is described as an oral small-molecule drug that acts on two molecular targets, PPAR-alpha and PPAR-gamma, which together regulate how the body handles fats and sugars [1]. The source states that it is being evaluated in the EPICS-III trial as a treatment for primary biliary cholangitis, a liver disease that differs from the drug's original metabolic indications [1]. The market's yes and no prices are snapshots taken at the observation time and are not executable quotes or verified probabilities. A price should not be read as a confirmed chance of approval.
Historical Context
The source states that saroglitazar is sold under the brand name Lipaglyn in India and was originally associated with metabolic indications [1]. It also states that the drug is now being evaluated in the EPICS-III trial for primary biliary cholangitis, a liver disease distinct from those original uses [1]. The supplied evidence does not describe the drug's wider regulatory history.
Why It Matters
The contract measures whether the FDA's 2026 decision on saroglitazar will be a full or accelerated approval, which would resolve to Yes, or a different outcome, which would resolve to No [1]. Because a conditional approval, a withdrawal, a CRL, or no decision all resolve to No, the wording of the rules determines what counts as a Yes [1]. The contract's expected close is also tied to whether the FDA acts before January 1, 2027 [1].
Snapshot context
The latest published provider snapshot for this topic was observed on 2026-11-11 at 00:00 UTC. It contains listings from Kalshi. Market descriptions and listed closing times define the contracts; they do not establish that the real-world outcome has occurred. This article does not include a separately verified news update. [1]
Frequently Asked Questions
What counts as a Yes resolution?
According to the listed rules, the market resolves to Yes if the FDA's decision on saroglitazar is a full approval or an accelerated approval [1].
Does a conditional approval resolve the contract?
A conditional approval resolves the market to No under the listed rules [1].
What happens if the FDA issues no decision in 2026?
The rules state that the market resolves to No if no decision is issued [1]. The source also says the market closes early if a decision is issued before January 1, 2027 [1].
Does the yes price show the probability of approval?
No. The price is a snapshot from the provider data and is not a verified probability or an executable quote. The rules themselves define the resolution criteria [1].
AI-written background. References identify the evidence used; Wikipedia links under Learn More are additional reading. Prices and provider rules are dated snapshots. This is not financial advice.
Related prediction markets
Prices are catalog snapshots and may have changed. Check each market's rules and observation time.

FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)
K 75.66 contracts
FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
K 4.2K contracts
FDA decision: BBP-418 by Ml Bio Solutions Inc. (in 2026)
K 944.1 contracts
FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)
K 41.42 contracts
When will Beam Therapeutics submit a BLA for Risto-cel?
K 11.2K contracts
When will Trump nominate an FDA commissioner?
K 1.6K contractsMarket Insights
Price gaps of 2 pp+
0
Same-question pairs
0
No outcomes on this page have been reviewed as the same question on both platforms yet.
Price differences do not establish arbitrage. Check each pair's review, current order prices, fees and settlement rules.
